Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2
- PMID: 8751855
- PMCID: PMC1914911
Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2
Abstract
The common hereditary forms of breast cancer have been largely attributed to the inheritance of mutations in the BRCA1 or BRCA2 genes. However, it is not yet clear what proportion of hereditary breast cancer is explained by BRCA1 and BRCA2 or by some other unidentified susceptibility gene(s). We describe the proportion of hereditary breast cancer explained by BRCA1 or BRCA2 in a sample of North American hereditary breast cancers and assess the evidence for additional susceptibility genes that may confer hereditary breast or ovarian cancer risk. Twenty-three families were identified through two high-risk breast cancer research programs. Genetic analysis was undertaken to establish linkage between the breast or ovarian cancer cases and markers on chromosomes 17q (BRCA1) and 13q (BRCA2). Mutation analysis in the BRCA1 and BRCA2 genes was also undertaken in all families. The pattern of hereditary cancer in 14 (61%) of the 23 families studied was attributed to BRCA1 by a combination of linkage and mutation analyses. No families were attributed to BRCA2. Five families (22%) provided evidence against linkage to both BRCA1 and BRCA2. No BRCA1 or BRCA2 mutations were detected in these five families. The BRCA1 or BRCA2 status of four families (17%) could not be determined. BRCA1 and BRCA2 probably explain the majority of hereditary breast cancer that exists in the North American population. However, one or more additional genes may yet be found that explain some proportion of hereditary breast cancer.
Similar articles
-
Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage.Cancer. 1996 Feb 15;77(4):697-709. doi: 10.1002/(sici)1097-0142(19960215)77:4<697::aid-cncr16>3.0.co;2-w. Cancer. 1996. PMID: 8616762
-
BRCA1 and BRCA2 in breast cancer.Breast Cancer Res Treat. 1999 Mar;54(1):1-10. doi: 10.1023/a:1006189906896. Breast Cancer Res Treat. 1999. PMID: 10369075 Review.
-
Breast cancer susceptibility genes. BRCA1 and BRCA2.Medicine (Baltimore). 1998 May;77(3):208-26. doi: 10.1097/00005792-199805000-00006. Medicine (Baltimore). 1998. PMID: 9653432 Review.
-
Confirmation of susceptibility locus on chromosome 13 in Australian breast cancer families.Hum Genet. 1996 Jul;98(1):80-5. doi: 10.1007/s004390050164. Hum Genet. 1996. PMID: 8682513
-
Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.J Clin Oncol. 2001 Apr 15;19(8):2247-53. doi: 10.1200/JCO.2001.19.8.2247. J Clin Oncol. 2001. PMID: 11304778
Cited by
-
An ELISA-based high throughput protein truncation test for inherited breast cancer.Breast Cancer Res. 2010;12(5):R78. doi: 10.1186/bcr2722. Epub 2010 Oct 4. Breast Cancer Res. 2010. PMID: 20920338 Free PMC article.
-
Age and Geographical Distribution in Families with BRCA1/BRCA2 Mutations in the Slovak Republic.Hered Cancer Clin Pract. 2006 Dec 15;4(1):7-11. doi: 10.1186/1897-4287-4-1-7. Hered Cancer Clin Pract. 2006. PMID: 20223009 Free PMC article.
-
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.Am J Hum Genet. 1997 May;60(5):1068-78. Am J Hum Genet. 1997. PMID: 9150154 Free PMC article.
-
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.Nat Rev Clin Oncol. 2017 May;14(5):284-296. doi: 10.1038/nrclinonc.2016.191. Epub 2016 Dec 13. Nat Rev Clin Oncol. 2017. PMID: 27958297 Review.
-
GENETIC DUTIES.William Mary Law Rev. 2020 Oct;62(1):143-211. William Mary Law Rev. 2020. PMID: 37654734 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous